Aardvark Therapeutics AARD
NASDAQ AARD
$1.35 -0.02 (-1.14%)
As of: Nov 11, 2026 · 9:50 AM EST

Aardvark Therapeutics (AARD) Accumulated Expenses (2023 - 2026)

Updated

Aardvark Therapeutics (AARD) recorded Accumulated Expenses of $3.9 million in Q2 2026, down 19.4% from $4.84 million a year earlier and down 42.4% from the prior quarter.

Analysis

Aardvark Therapeutics (AARD) Accumulated Expenses (2023 - 2026) Analysis & Trends

At the end of FY2025, Aardvark Therapeutics reported Accumulated Expenses of $8.04 million, up 250.7% from FY2024.

  • Across earlier years, Accumulated Expenses came in at $2.29 million in FY2024.
  • The Q2 2026 figure is the lowest quarterly Accumulated Expenses since Q1 2025.
  • Per Business Quant, the preceding three quarters came in at $6.78 million (Q1 2026), $8.04 million (Q4 2025) and $5.86 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Aardvark Therapeutics 29.98 Mn -43.92 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.90 Mn
Mar 31, 2026 6.78 Mn
Dec 31, 2025 8.04 Mn
Sep 30, 2025 5.86 Mn
Jun 30, 2025 4.84 Mn
Mar 31, 2025 3.03 Mn
Dec 31, 2024 2.29 Mn
Dec 31, 2023 235,000.00
API Access

Aardvark Therapeutics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=AARD&period=max&api_key=YOUR_API_KEY